Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating yesterday. Graig ...

Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024 Operating profit increased by ...

Monlunabant was evaluated in a phase 2a trial (ClinicalTrials.gov Identifier: NCT05891834) in patients with obesity and metabolic syndrome (N=243). Results showed patients treated with monlunabant ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to ...

However, shares in Novo Nordisk fell by nearly five per cent last month, after the company reported disappointing results from a phase 2a trial of its experimental obesity pill, monlunabant.

Circle to Search is coming to compatible phones with OxygenOS 15 The update also adds new boot animation, icons, and shelf card choices OxygenOS 15 introduces Gemini-powered AI Notes ...

Based on these results a phase 2b trial is expected to begin in 2025. The larger trial will further assess monlunabant in obese patients over a longer duration. Results from a phase 2 trial ...

Novo is developing its own oral weight-loss drugs. Recent data has shown that Monlunabant, Novo’s once-a-day pill, has achieved statistically significant weight loss, however, it also showed ...